Abstract

Parkinson's disease (PD) is a heterogeneous neurodegenerative disease that belongs to the family of synucleiopathies, varying according to age, symptoms and progression. The hallmark of the disease is the accumulation of misfolded alpha-synuclein (α-Syn) protein in neuronal and non-neuronal brain cells. Over the past decades, the diagnosis and treatment of PD had a view centred on motoric endpoint and deficits in the nigrostriatal dopaminergic system, and consequently animal models of PD with predominantly motor behavior deficits have been used to study the disease. However, clinical trials have failed to translate results from animal models into successful treatments. PD as a multisystem disorder therefore requires additional assessment of early non-motor symptoms. Braak’s staging revealed early α-Syn pathology in the pontine brainstem and olfactory circuits controlling rapid eye movement sleep behavior disorder (RBD) and olfaction, respectively. Recent converging evidence from multicenter clinical trials points to RBD as the most important functional risk marker for prodromal PD and conducting neuroprotective therapeutic trials in RBD-enriched cohorts has been recommended. Animal models of RBD and olfactory dysfunction may help bridge the translational research gap in precision drug discovery for PD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call